ProCE Banner Activity

My Thoughts on the Evolving Treatment Landscape for Hemophilia A

Clinical Thought
Factor replacement therapies and newer nonfactor agents offer the ability to tailor therapy for individual patients with hemophilia A. Additional therapies in late-stage development are poised to further alter the treatment landscape. Read an expert’s thoughts on how these new therapies might fit into the existing treatment paradigms in hemophilia A.

Released: October 14, 2021

Expiration: October 13, 2022

Share

Faculty

Miguel A. Escobar

Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Division of Hematology
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Sanofi Genzyme

Takeda Pharma USA Inc Takeda Onc Co

Program Director Disclosure

Program Director

Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Division of Hematology
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Miguel A. Escobar, MD, has disclosed that he has received funds for research support from CSL Behring, Genentech, Novo Nordisk, Sanofi, Takeda, and UniQure (paid to institution) and consulting fees from CSL Behring, BioMarin, Genentech/Roche, HEMA Biologics , Kedrion, NHF, Novo Nordisk, Pfizer, Sanofi, and Takeda.

Staff Disclosure

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.